These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 35032500)

  • 1. Clinical Care Pathway for the Risk Stratification and Management of Patients With Non-alcoholic Fatty Liver Disease.
    Sullivan S; Jirapinyo P; Kumbhari V
    Gastroenterology; 2022 Jun; 162(7):2131-2132. PubMed ID: 35032500
    [No Abstract]   [Full Text] [Related]  

  • 2. Non-alcoholic fatty liver disease and the interface between primary and secondary care.
    Tsochatzis EA; Newsome PN
    Lancet Gastroenterol Hepatol; 2018 Jul; 3(7):509-517. PubMed ID: 29893235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease.
    Rinella ME; Neuschwander-Tetri BA; Siddiqui MS; Abdelmalek MF; Caldwell S; Barb D; Kleiner DE; Loomba R
    Hepatology; 2023 May; 77(5):1797-1835. PubMed ID: 36727674
    [No Abstract]   [Full Text] [Related]  

  • 4. Managing non-alcoholic fatty liver disease.
    Ngu JH; Goh GB; Poh Z; Soetikno R
    Singapore Med J; 2016 Jul; 57(7):368-71. PubMed ID: 27439352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk stratification of patients with nonalcoholic fatty liver disease using a case identification pathway in primary care: a cross-sectional study.
    Shaheen AA; Riazi K; Medellin A; Bhayana D; Kaplan GG; Jiang J; Park R; Schaufert W; Burak KW; Sargious M; Swain MG
    CMAJ Open; 2020; 8(2):E370-E376. PubMed ID: 32414883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How to Approach a Patient With Nonalcoholic Fatty Liver Disease.
    Tilg H
    Gastroenterology; 2017 Aug; 153(2):345-349. PubMed ID: 28647352
    [No Abstract]   [Full Text] [Related]  

  • 7. Referral care paths for non-alcoholic fatty liver disease-Gearing up for an ever more prevalent and severe liver disease.
    van Dijk AM; Schattenberg JM; Holleboom AG; Tushuizen ME
    United European Gastroenterol J; 2021 Oct; 9(8):903-909. PubMed ID: 34609086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver Biopsy in Chronic Liver Diseases: Is There a Favorable Benefit: Risk Balance?
    Larrey D; Meunier L; Ursic-Bedoya J
    Ann Hepatol; 2017; 16(4):487-489. PubMed ID: 28612749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-alcoholic fatty liver disease: a review of epidemiology, risk factors, diagnosis and management.
    Huang TD; Behary J; Zekry A
    Intern Med J; 2020 Sep; 50(9):1038-1047. PubMed ID: 31760676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Implications of the American Gastroenterology Association Nonalcoholic Fatty Liver Disease Clinical Care Pathway in the US Adult Population.
    Xu X; Alanaeme J; Wen Y; Colantonio LD; Muntner P; Long MT
    Gastroenterology; 2023 Apr; 164(4):688-689.e4. PubMed ID: 36623777
    [No Abstract]   [Full Text] [Related]  

  • 11. Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age?
    Firneisz G
    World J Gastroenterol; 2014 Jul; 20(27):9072-89. PubMed ID: 25083080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-alcoholic fatty liver disease (NAFLD): summary of NICE guidance.
    Glen J; Floros L; Day C; Pryke R;
    BMJ; 2016 Sep; 354():i4428. PubMed ID: 27605111
    [No Abstract]   [Full Text] [Related]  

  • 13. Modern approach to the clinical management of non-alcoholic fatty liver disease.
    Del Ben M; Polimeni L; Baratta F; Pastori D; Loffredo L; Angelico F
    World J Gastroenterol; 2014 Jul; 20(26):8341-50. PubMed ID: 25024593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-alcoholic fatty liver disease and hepatocellular carcinoma: Clinical challenges of an intriguing link.
    Chrysavgis L; Giannakodimos I; Diamantopoulou P; Cholongitas E
    World J Gastroenterol; 2022 Jan; 28(3):310-331. PubMed ID: 35110952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implementing the right care in the right place at the right time for non-alcoholic fatty liver disease (NAFLD-RRR study): a study protocol for a community care pathway for people with type 2 diabetes.
    Gracen L; Hayward KL; Aikebuse M; Russell A; O'Beirne J; McPhail S; Irvine KM; Williams S; Valery PC; Powell EE
    BMC Health Serv Res; 2022 Apr; 22(1):487. PubMed ID: 35413987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in patients with HIV.
    Verna EC
    Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):211-223. PubMed ID: 28404136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Non-alcoholic fatty liver disease (NAFLD)].
    Rau M; Weiss J; Geier A
    Dtsch Med Wochenschr; 2015 Jul; 140(14):1051-5. PubMed ID: 26182253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-alcoholic fatty liver disease and cardiovascular risk: an update.
    Mullish BH; Forlano R; Manousou P; Mikhailidis DP
    Expert Rev Gastroenterol Hepatol; 2018 Dec; 12(12):1175-1177. PubMed ID: 30791787
    [No Abstract]   [Full Text] [Related]  

  • 19. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update.
    Athyros VG; Tziomalos K; Katsiki N; Doumas M; Karagiannis A; Mikhailidis DP
    World J Gastroenterol; 2015 Jun; 21(22):6820-34. PubMed ID: 26078558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Epidemiology of non-alcoholic steatohepatitis. Extent/burden of the problem and its impact on public health].
    Vallet-Pichard A; Parlati L; Pol S
    Presse Med; 2019 Dec; 48(12):1459-1467. PubMed ID: 31757728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.